Search Results - "Lee, Elizabeth Katherine"

A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors by Spira, Alexander I., Lee, Elizabeth Katherine, O'Cearbhaill, Roisin Eilish, LoRusso, Patricia, Falchook, Gerald Steven, Patel, Manish R., Richardson, Debra L., Covino, Nicole, Lu, Wei, Marreddy, Priya, Farrington, Daphne L., Wheler, Jennifer J., Slosberg, Eric Daniel, Subbiah, Vivek, Meric-Bernstam, Funda

“…TPS3166 Background: Cadherin-6 (CDH6) is a transmembrane glycoprotein involved in cancer metastasis and invasion expressed in various tumor types including…”
Get full text

First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations by Yap, Timothy A., Lakhani, Nehal J., Patnaik, Amita, Lee, Elizabeth Katherine, Gutierrez, Martin, Moore, Kathleen N., Carneiro, Benedito A., Hays, John L., Huang, Marilyn, LoRusso, Patricia, Wylie, Andrew, Cadzow, Louise, Goulet, Matthew, Tobin, Erica, Krieter, Oliver, Schmid, Daniela, Blake, Sophia M., Dieterich, Max, Jamois, Candice, Harris, Patricia M.

“…3005 Background: USP1 is a deubiquitinase that regulates DNA damage response pathways, such as Translesion Synthesis and Fanconi Anemia pathways. KSQi is a…”
Get full text

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses by Konstantinopoulos, Panagiotis A., Lee, Elizabeth Katherine, Cheng, SuChun, Da Costa, Alexandre Andre B. A., Wahner Hendrickson, Andrea Elisabeth, Gulhan, Doga, Kochupurakkal, Bose, Kolin, David, Kohn, Elise C., Liu, Joyce F., Stover, Elizabeth, Curtis, Jennifer, Sawyer, Hannah, Polak, Madeline, Chowdhury, Dipanjan, Färkkilä, Anniina, D'Andrea, Alan D., Shapiro, Geoffrey, Matulonis, Ursula A.

“…5512 Background: The multicenter, open-label, randomized phase 2 NCI-9944 study (NCT02595892) demonstrated that addition of ATR inhibitor (ATRi) berzosertib to…”
Get full text

Phase 2, multicenter, open-label basket trial of nab -sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) by Iyer, Gopa, Deming, Dustin A., Demeure, Michael J., Federman, Noah, McKean, Meredith, Lee, Elizabeth Katherine, Spira, Alexander I., Kwiatkowski, David J., Hussein, Maen A., Gordon, Erlinda Maria, Crockett, David G., Ganjoo, Kristen N., Schulte, Brian, Cranmer, Lee D., Ding, Li, Schmid, Anita N., Navarro, Willis H., Rodon Ahnert, Jordi

“…TPS3168 Background: nab-Sirolimus is a novel albumin-bound mTOR inhibitor (mTORi) approved in the US for adult patients with malignant PEComa. In an…”
Get full text

A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC) by Lee, Elizabeth Katherine, Xiong, Niya, Cheng, SuChun, Polak, Madeline, Krasner, Carolyn N., Campos, Susana M., Wright, Alexi A., Liu, Joyce F., Shea, Meghan, Yeku, Oladapo O., Castro, Cesar Martin, Porter, Rebecca L, Stover, Elizabeth, Bouberhan, Sara, Moroney, John William, Penson, Richard T., Fleming, Gini F., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.

“…TPS5628 Background: Despite significant strides in understanding the molecular pathogenesis of EC, there remain few effective therapies for recurrent disease…”
Get full text

Phase 2, multicenter, open-label basket trial of nab -sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) by Iyer, Gopa, Demeure, Michael J., Deming, Dustin A., Federman, Noah, McKean, Meredith, Lee, Elizabeth Katherine, Spira, Alexander I., Kwiatkowski, David J., Hussein, Maen A., Gordon, Erlinda Maria, Crockett, David G., Ganjoo, Kristen N., Schulte, Brian, Cranmer, Lee D., Schmid, Anita N., Navarro, Willis H., Itri, Loretta Marie

“…TPS597 Background: Albumin-bound ( nab)-sirolimus, a novel mTOR inhibitor (mTORi) that utilizes nanoparticle technology to preferentially target tumors, is…”
Get full text

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) by Deming, Dustin A., Rodon Ahnert, Jordi, Demeure, Michael J., Federman, Noah, McKean, Meredith, Lee, Elizabeth Katherine, Spira, Alexander I., Kwiatkowski, David J., Hussein, Maen A., Gordon, Erlinda Maria, Crockett, David G., Ganjoo, Kristen N., Schulte, Brian, Cranmer, Lee D., Schmid, Anita N., Navarro, Willis H., Itri, Loretta Marie, Iyer, Gopa

“…TPS818 Background: Albumin-bound ( nab)-sirolimus, a novel mTOR inhibitor (mTORi) that utilizes nanoparticle technology to preferentially target tumors, is…”
Get full text

A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC) by Porter, Rebecca L., Veneris, Jennifer Taylor, Tayob, Nabihah, West, Gabriela, Polak, Madeline, Gardner, Jeanette, Campos, Susana M., Krasner, Carolyn N., Lee, Elizabeth Katherine, Liu, Joyce F., Stover, Elizabeth, Wright, Alexi A., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.

“…Abstract only TPS5611 Background: Folate receptor-alpha (FRα) is expressed on endometrial cancer (EC) cells and is associated with poor prognosis. Mirvetuximab…”
Get full text

Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116) by Rosen, Ezra, Silverman, Ian M., Fontana, Elisa, Lee, Elizabeth Katherine, Spigel, David R., Højgaard, Martin, Lheureux, Stephanie, Mettu, Niharika B., Carneiro, Benedito A., Carter, Louise, Plummer, Elizabeth Ruth, Schonhoft, Joseph D., Ulanet, Danielle, Manley, Peter, Reis-Filho, Jorge S., Xu, Yi, Rimkunas, Victoria, Koehler, Maria, Yap, Timothy A.

“…3082 Background: RP-3500 is a selective and potent oral ATRi in development for advanced solid tumors harboring loss-of-function (LOF) alterations in genes…”
Get full text

A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC) by Lee, Elizabeth Katherine, Xiong, Niya, Tayob, Nabihah, Krasner, Carolyn N., Buss, Mary K., Campos, Susana M., Wright, Alexi A., Liu, Joyce F., Shea, Meghan, Yeku, Oladapo O., Castro, Cesar Martin, Porter, Rebecca L, Stover, Elizabeth, Bouberhan, Sara, Moroney, John William, Cannistra, Stephen A., Penson, Richard T., Fleming, Gini F., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.

“…Abstract only TPS5609 Background: Despite significant strides in understanding the molecular pathogenesis of EC, there remain few effective therapies for…”
Get full text